Concepedia

Publication | Open Access

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

18

Citations

24

References

2024

Year

Abstract

This study provides Class IV evidence that eculizumab reduces annualized attack rates and new MRI lesions in AQP4-IgG+ patients with NMOSD.

References

YearCitations

Page 1